PFAPA综合征儿童的腮腺炎、麻疹和风疹疫苗接种
该研究评估了31例PFAPA综合征患儿和22名健康对照儿童接种一剂MMR疫苗后的麻疹、腮腺炎和风疹免疫水平。PFAPA组麻疹和风疹保护性抗体比例与对照组无显著差异,但腮腺炎保护性抗体比例显著低于对照组。作者认为PFAPA患儿对麻疹和风疹组分应答良好,但一剂MMR后的腮腺炎免疫可能不足,需进一步研究。
要点
- PFAPA患儿麻疹保护性抗体比例93.55% vs 健康对照95.45%(p=0.77),无显著差异。
- PFAPA患儿腮腺炎保护性抗体比例74.19% vs 健康对照95.45%(p=0.02),显著低于对照。
- PFAPA患儿风疹保护性抗体比例80.65% vs 健康对照90.9%(p=0.30),无显著差异。
核心结论
- PFAPA综合征患儿对MMR疫苗的麻疹和风疹组分应答良好,但接种一剂MMR后的腮腺炎免疫可能不足。
- 作者认为需进一步研究周期性发热综合征患儿对疫苗可预防疾病的免疫及疫苗接种安全性。
研究设计与样本
- 研究纳入31例PFAPA综合征患儿和22名健康对照儿童,所有儿童均按波兰义务接种程序既往接种过一剂MMR疫苗。
- 采用ELISA法检测两组儿童抗麻疹、抗腮腺炎和抗风疹IgG抗体浓度,保护性抗体参考值分别为150IU/L、16RU/L和11IU/ml。
主要发现
- 麻疹保护性抗体比例:PFAPA组93.55% vs 健康对照组95.45%(p=0.77)。
- 腮腺炎保护性抗体比例:PFAPA组74.19% vs 健康对照组95.45%(p=0.02)。
- 风疹保护性抗体比例:PFAPA组80.65% vs 健康对照组90.9%(p=0.30)。
关键数值与推荐
- 保护性抗体参考值:抗麻疹IgG 150IU/L,抗腮腺炎IgG 16RU/L,抗风疹IgG 11IU/ml。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究周期性发热综合征患儿对疫苗可预防疾病的免疫及疫苗接种安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: There is no published data regarding immunologic response to vaccinations in children with PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis). The aim of this study was to evaluate mumps, measles and rubella immunity in children with PFAPA. 31 children with PFAPA syndrome and 22 healthy children (control group - CG) were recruited to the study. All children were previously vaccinated with one dose of MMR vaccine according to the Polish obligatory vaccination schedule. The patients from both groups were evaluated for anti-measles, anti-mumps and anti-rubella IgG antibodies concentrations (ELISA tests; the reference values for protective antibody levels were 150IU/L, 16RU/L and 11IU/ml respectively). The percentage of patients with protective antibodies levels was as follows: measles - 93.55% of PFAPA and 95.45% of CG patients (p=0.77); mumps - 74.19% of PFAPA and 95.45% of CG patients (p=0.02); rubella - 80.65% of PFAPA and 90.9% of CG patients (p=0.30). CONCLUSIONS: Children with PFAPA syndrome present a good response to the measles and rubella component of the MMR vaccine, however immunity against mumps after one dose of MMR may not be sufficient. Further investigation concerning immunity against vaccine-preventable diseases and the safety of vaccinations in children with periodic fever syndromes is required.
引用
- Kraszewska-Głomba B, Matkowska-Kocjan A, Miśkiewicz K, et al. Mumps, measles and rubella vaccination in children with PFAPA syndrome. Vaccine. 2016. PMID: 27997341. doi:10.1016/j.vaccine.2016.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。